Cover Image

Integrated analyses reveal IDO1 as a prognostic biomarker coexpressed with PD-1 on tumor-associated macrophages in esophageal squamous cell carcinoma

BackgroundInhibition of indolamine-2,3-dioxygenase 1 (IDO1) has been proposed as a promising strategy for cancer immunotherapy; however, it has failed in clinical trials. Macrophages in the tumor microenvironment (TME) contribute to immune escape and serve as potential therapeutic targets. This stud...

Full description

Saved in:

Bibliographic Details
Main Authors:	Yaojun Peng (Author), Lingxiong Wang (Author), Juan Yang (Author), Qiyan Wu (Author), Xiaoxuan Sun (Author), Jinying Zhang (Author), Yanju Yu (Author), Liping Zhang (Author), Jie Gao (Author), Qing Zhou (Author), Haiyan Zhu (Author), Fan Yin (Author)
Format:	Book
Published:	Frontiers Media S.A., 2024-09-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Sodium Tanshinone IIA Sulfonate as a Potent IDO1/TDO2 Dual Inhibitor Enhances Anti-PD1 Therapy for Colorectal Cancer in Mice
by: Rongjie Zhang, et al.
Published: (2022)

Qishen Granule Improved Cardiac Remodeling via Balancing M1 and M2 Macrophages
by: Wenji Lu, et al.
Published: (2019)

Sequential delivery of PD-1/PD-L1 blockade peptide and IDO inhibitor for immunosuppressive microenvironment remodeling via an MMP-2 responsive dual-targeting liposome
by: Chuan Hu, et al.
Published: (2023)

Identifying Macrophage-Related Genes in Ulcerative Colitis Using Weighted Coexpression Network Analysis and Machine Learning
by: Shaocheng Hong, et al.
Published: (2023)

Novel phthalimides regulating PD-1/PD-L1 interaction as potential immunotherapy agents
by: Chengliang Sun, et al.
Published: (2022)

Dual gene‐activated dermal scaffolds regulate angiogenesis and wound healing by mediating the coexpression of VEGF and angiopoietin‐1
by: Tingting Weng, et al.
Published: (2023)

Tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for hepatocellular carcinoma: recent research progress
by: Ziwei Li, et al.
Published: (2024)

PD-1 Inhibitors in the Advanced Esophageal Cancer
by: Ye Hong, et al.
Published: (2019)

Identification of biomarkers and pathogenesis in severe asthma by coexpression network analysis
by: Zeyi Zhang, et al.
Published: (2021)

Design, synthesis and biological evaluation of erlotinib-based IDO1 inhibitors
by: Xi-xi Hou, et al.
Published: (2022)

Discovery of Icotinib-1,2,3-Triazole Derivatives as IDO1 Inhibitors
by: Long-fei Mao, et al.
Published: (2020)

Notoginsenoside R1 Ameliorates Cardiac Lipotoxicity Through AMPK Signaling Pathway
by: Xue Tian, et al.
Published: (2022)

Expression of immune checkpoint regulators, programmed death-ligand 1 (PD-L1/PD-1), cytotoxic T lymphocyte antigen 4 (CTLA-4), and indolaimine-2, 3-deoxygenase (IDO) in uterine mesenchymal tumors
by: Alireza Samiei, et al.
Published: (2022)

CSF1R inhibition reprograms tumor-associated macrophages to potentiate anti-PD-1 therapy efficacy against colorectal cancer
by: Qi Lv, et al.
Published: (2024)

Cancer Cell Secreted Legumain Promotes Gastric Cancer Resistance to Anti-PD-1 Immunotherapy by Enhancing Macrophage M2 Polarization
by: Xu Pei, et al.
Published: (2024)

Different Induction of PD-L1 (CD274) and PD-1 (CD279) Expression in THP-1-Differentiated Types 1 and 2 Macrophages
by: Lai CY, et al.
Published: (2021)

TCR Coexpression Signature Predicts Immunotherapy Resistance in NSCLC
by: Yuntao Wang, et al.
Published: (2022)

Resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives
by: Jin-Yu Sun, et al.
Published: (2020)

Editorial: Toxicity mechanism and clinical features of PD-1/PD-l1 inhibitors in treatment of cancer, volume II
by: Chuqi Lei, et al.
Published: (2023)

Discovery of secondary sulphonamides as IDO1 inhibitors with potent antitumour effects in vivo
by: Shushan Ge, et al.
Published: (2020)

miR-409 Inhibits Human Non-Small-Cell Lung Cancer Progression by Directly Targeting SPIN1
by: Qi Song, et al.
Published: (2018)

Discovery of Novel 1,2,3-triazole Derivatives as IDO1 Inhibitors
by: Xixi Hou, et al.
Published: (2022)

A bibliometric analysis of research on PD-1/PD-L1 in urinary tract tumors
by: Yongming Chen, et al.
Published: (2024)

PD-1/PD-L1 Inhibitors in Patients With Preexisting Autoimmune Diseases
by: Ke Zhang, et al.
Published: (2022)

Association of PD-1/PD-L1 expression and Epstein--Barr virus infection in patients with invasive breast cancer
by: Wei-tong Zhang, et al.
Published: (2022)

Human Leukocyte Antigen Class I and Programmed Death-Ligand 1 Coexpression Is an Independent Poor Prognostic Factor in Adenocarcinoma of the Lung
by: Yeon Bi Han, et al.
Published: (2019)

PD-1/PD-L1 Based Combinational Cancer Therapy: Icing on the Cake
by: Jian-ye Zhang, et al.
Published: (2020)

Percentages of PD-1+CD4+T cells and PD-L1+DCs are increased and sPD-1 level is elevated in patients with immune thrombocytopenia
by: Yingying Wang, et al.
Published: (2018)

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
by: Jinhua Liu, et al.
Published: (2021)

cRGD peptide-conjugated polyethylenimine-based lipid nanoparticle for intracellular delivery of siRNA in hepatocarcinoma therapy
by: Shuang Yang, et al.
Published: (2021)

Resistance to Cetuximab in EGFR-Overexpressing Esophageal Squamous Cell Carcinoma Xenografts Due to FGFR2 Amplification and Overexpression
by: Yi Zhang, et al.
Published: (2014)

The Coevolution of IDO1 and AhR in the Emergence of Regulatory T Cells in Mammals
by: Ursula Grohmann
Published: (2016)

Danqi Pill Protects Against Heart Failure Post-Acute Myocardial Infarction via HIF-1α/PGC-1α Mediated Glucose Metabolism Pathway
by: Qian Zhang, et al.
Published: (2020)

Delivery of antisense oligonucleotide using polyethylenimine-based lipid nanoparticle modified with cell penetrating peptide
by: Shuang Yang, et al.
Published: (2019)

PD-L1 on Circulating Tumor Cells Indicates Poor Prognosis in Breast Cancer
by: Xue-fei Wang, et al.
Published: (2022)

PD-1/PD-L1 pathway and angiogenesis dual recognizable nanoparticles for enhancing chemotherapy of malignant cancer
by: Zhenliang Sun, et al.
Published: (2018)

A preliminary study on Fructus Aurantii extract against hepatocarcinoma via glycolysis and PD-1/PD-L1 pathway
by: Xi Luo, et al.
Published: (2022)

Single-cell analyses reveal cannabidiol rewires tumor microenvironment via inhibiting alternative activation of macrophage and synergizes with anti-PD-1 in colon cancer
by: Xiaofan Sun, et al.
Published: (2023)

Necrostatin-1 Prevents Ferroptosis in a RIPK1- and IDO-Independent Manner in Hepatocellular Carcinoma
by: Hanna Yuk, et al.
Published: (2021)

Blocking the PD-1/PD-L1 axis enhanced cisplatin chemotherapy in osteosarcoma in vitro and in vivo
by: Xiaoqiang Liu, et al.
Published: (2019)